Corporate Profile
AVI BioPharma is a biopharmaceutical company developing drugs to treat life–threatening diseases using its patented third–generation antisense technology. We have completed eleven clinical trials with our NeuGene® antisense drugs in more than 300 subjects addressing cardiovascular restenosis, infectious disease, cancer, polycystic kidney disease and drug metabolism. In clinical studies, our novel antisense drugs have been well–tolerated and have met efficacy endpoints.
We are focusing further clinical development on cardiovascular and infectious disease indications. Our most advanced cardiovascular program is for restenosis where we have completed Phase II trials evaluating our drug, Resten–NG®. We are currently evaluating a systemic formulation of this drug in additional Phase II studies in Europe.
We are also evaluating our drug candidates in patients with viral infectious diseases. Our NeuGene drugs have shown antiviral activity in preclinical and field trials against a broad group of RNA viruses, including hepatitis C virus, Influenza A virus, West Nile virus, SARS coronavirus, Dengue virus, Ebola virus and Marburg virus. We are currently in a Phase II clinical trial with a drug for Hepatitis C infection and our Influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies.
| Program | Indication | Technology | Clinical Stage |
|---|---|---|---|
| Cardiovascular | Restenosis, stents | NeuGene | Phase II |
| Restenosis, IV-MP | NeuGene | Phase II | |
| CABG | NeuGene | Phase Ib/II | |
| Infectious Disease | Bioterrorism Agents (Ebola, Marburg, Anthrax, Ricin) | NeuGene | Preclinical |
| Influenza A (H5N1) | NeuGene | Preclinical | |
| Dengue Fever | NeuGene | Preclinical | |
| Other | Muscular Dystrophy | ESPRIT | Phase I/II |
| Drug Metabolism | NeuGene | Phase Ib |